Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel by Francesco Bertolini.
Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel by Francesco Bertolini.
复制标题
DOI：
10.1387/ijdb.103217fb
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Kerbel, Robert
中科院分区：
文献类型：
--
作者：
Kerbel, Robert
罗伯特·科贝尔是癌症相关血管生成和抗血管生成疗法领域最有影响力的科学家之一。与已故的朱达·福克曼一起，科贝尔博士还开创了使用持续低剂量化疗治疗癌症的先河，这种方法现在被广泛用于许多类型的癌症，是与新的靶向治疗相关的有前景的支柱。在这次采访中，科贝尔博士描述了将他的职业生涯推向血管生成领域的步骤、已经取得的生物学和临床结果以及尚未实现的目标。
Robert Kerbel is one of the most influential scientists in the field of cancer-related angiogenesis and anti-angiogenic therapies. Along with the late Judah Folkman, Dr. Kerbel has also pioneered the use of continuous low dose chemotherapy for cancer treatment, an approach which is now widely used for many types of cancer and is a promising backbone to be associated with novel targeted therapies. In this interview, Dr. Kerbel describes the steps that moved his career towards the angiogenesis field, the already achieved biological and clinical results and the unmet goals.